Therapeutic Solutions International Inc (TSOI)

[centsability4me]

yes,

Intrexon Completes Acquisition of Medistem

https://www.prnewswire.com/news-releases/intrexon-completes-acquisition-of-medistem-248984811.html

GERMANTOWN, Md. and SAN DIEGO, March 7, 2014 /PRNewswire/ -- Intrexon Corporation ( NYSE: XON), a leader in synthetic biology, today announced that it has completed the acquisition of San Diego-based Medistem, Inc. ( OTCQB: MEDS), a pioneer in the development of Endometrial Regenerative Cells ("ERC" or "ERCs"), universal donor adult-derived stem cells with properties uniquely suited for therapeutic use with Intrexon's existing suite of synthetic biology technologies. Upon integration of these platforms, ERCs could be manufactured as genetically modified vehicles to secrete powerful therapeutic effectors in the body for clinical benefit to patients suffering from many different diseases.

In combination with Intrexon's diverse proprietary suite of technologies, including its UltraVector® gene engineering and assembly, RheoSwitch Therapeutic System® platform, and Cell Systems Informatics, Medistem's ERCs have the potential to be utilized as vehicles to deliver novel genetically controlled therapies for conditions such as cancer, inflammation, and a number of orphan diseases. Intrexon looks forward to developing these compelling technologies and making them available to existing and future collaborators.

Thomas Ichim, Ph.D., former President and Chief Science Officer of Medistem, has agreed to join the Intrexon team within its Cell Engineering Unit. Under the terms of the agreement, Medistem stockholders will receive in exchange for each share of Medistem common stock $0.27 in cash and $1.08 worth of Intrexon common stock, or approximately 0.03920 shares, based on the 20-day volume-weighted average price of Intrexon's common stock immediately prior to closing, subject to adjustment pursuant to the terms of the merger agreement.